1. Germing U, Strupp C, Kundgen A, Bowen D, Aul C, Haas R, Gattermann N. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004;89(8):905–10.
2. de Swart L, Smith A, Fenaux P, Symenonidis A, Hellström-Lindberg E, Sanz G, Cermak J, Georgescu O, Germing U, MacKenzie M, Beyne-Rauzy O, Malcovati L, Stauder R, Droste J, Bowen D, de Witte T. Management of 1000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS Registry. Leuk Res. 2011; S3(7):Supplement 1.
3. Pfeilstöcker M, Karlic H, Nösslinger T, Sperr W, Stauder R, Krieger O, Valent P. Myelodysplasia and aging: differences and common features in biology and clinic. Leukemia and Lymphoma. 2007;48(10):1900–9.
4. Stauder R, Noesslinger T, Pfeilstöcker M, Sperr WR, Wimazal F, Krieger O, Valent P. Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;6(9):927–34.
5. Stauder R. The challenge of personalized risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Ann Hematol. 2012;91(9):1333–43.